Analysis: technical problem at Belgium plant failed to produce enough vaccine but EU demanding fulfilment of contract
AstraZeneca warned the European commission on Friday that there would be a significant shortfall in the promised 100m vaccine doses this quarter, of up to 60%. It says this is due to a technical issue: not enough vaccine is being produced by the main plant making the supplies destined for Europe, which is in Belgium.
